133 related articles for article (PubMed ID: 31434088)
1. Synergetic Effect of EP1 Receptor Antagonist and (-)-Epigallocatechin-3-gallate in Hepatocellular Carcinoma.
Yang H; Wang M; Sun H; Zhu S; Jin J
Pharmacology; 2019; 104(5-6):267-275. PubMed ID: 31434088
[TBL] [Abstract][Full Text] [Related]
2. Prostanoid EP1 receptor as the target of (-)-epigallocatechin-3-gallate in suppressing hepatocellular carcinoma cells in vitro.
Jin J; Chang Y; Wei W; He YF; Hu SS; Wang D; Wu YJ
Acta Pharmacol Sin; 2012 May; 33(5):701-9. PubMed ID: 22555372
[TBL] [Abstract][Full Text] [Related]
3. Green tea component epigallocatechin-3-gallate decreases expression of osteopontin via a decrease in mRNA half-life in cell lines of metastatic hepatocellular carcinoma.
Zapf MA; Kothari AN; Weber CE; Arffa ML; Wai PY; Driver J; Gupta GN; Kuo PC; Mi Z
Surgery; 2015 Oct; 158(4):1039-47; discussion 1047-8. PubMed ID: 26189955
[TBL] [Abstract][Full Text] [Related]
4. Involvement of the prostaglandin E receptor EP2 in paeoniflorin-induced human hepatoma cell apoptosis.
Hu S; Sun W; Wei W; Wang D; Jin J; Wu J; Chen J; Wu H; Wang Q
Anticancer Drugs; 2013 Feb; 24(2):140-9. PubMed ID: 23069790
[TBL] [Abstract][Full Text] [Related]
5. Prostaglandin E₂ receptor EP1-mediated phosphorylation of focal adhesion kinase enhances cell adhesion and migration in hepatocellular carcinoma cells.
Bai X; Wang J; Zhang L; Ma J; Zhang H; Xia S; Zhang M; Ma X; Guo Y; Rong R; Cheng S; Shu W; Wang Y; Leng J
Int J Oncol; 2013 May; 42(5):1833-41. PubMed ID: 23525457
[TBL] [Abstract][Full Text] [Related]
6. Prostaglandin E2 receptor EP1 transactivates EGFR/MET receptor tyrosine kinases and enhances invasiveness in human hepatocellular carcinoma cells.
Han C; Michalopoulos GK; Wu T
J Cell Physiol; 2006 Apr; 207(1):261-70. PubMed ID: 16331686
[TBL] [Abstract][Full Text] [Related]
7. Green tea polyphenol epigallocatechin-3-gallate inhibits thrombin-induced hepatocellular carcinoma cell invasion and p42/p44-MAPKinase activation.
Kaufmann R; Henklein P; Henklein P; Settmacher U
Oncol Rep; 2009 May; 21(5):1261-7. PubMed ID: 19360302
[TBL] [Abstract][Full Text] [Related]
8. Investigation of folate-modified EGCG-loaded thermosensitive nanospheres inducing immunogenic cell death and damage-associated molecular patterns in hepatocellular carcinoma.
He L; Peng L; Wang L; Jiang X; Sun X; Li H; Lin T; Wu Z; Lin S
Biochem Biophys Res Commun; 2024 Jun; 714():149976. PubMed ID: 38677007
[TBL] [Abstract][Full Text] [Related]
9. Prostaglandin E2 stimulates β1-integrin expression in hepatocellular carcinoma through the EP1 receptor/PKC/NF-κB pathway.
Bai X; Wang J; Guo Y; Pan J; Yang Q; Zhang M; Li H; Zhang L; Ma J; Shi F; Shu W; Wang Y; Leng J
Sci Rep; 2014 Oct; 4():6538. PubMed ID: 25289898
[TBL] [Abstract][Full Text] [Related]
10. Chemopreventive and hepatoprotective effects of Epigallocatechin-gallate against hepatocellular carcinoma: role of heparan sulfate proteoglycans pathway.
Darweish MM; Abbas A; Ebrahim MA; Al-Gayyar MM
J Pharm Pharmacol; 2014 Jul; 66(7):1032-45. PubMed ID: 24611903
[TBL] [Abstract][Full Text] [Related]
11. (-)-Epigallocatechin gallate suppresses the growth of human hepatocellular carcinoma cells by inhibiting activation of the vascular endothelial growth factor-vascular endothelial growth factor receptor axis.
Shirakami Y; Shimizu M; Adachi S; Sakai H; Nakagawa T; Yasuda Y; Tsurumi H; Hara Y; Moriwaki H
Cancer Sci; 2009 Oct; 100(10):1957-62. PubMed ID: 19558547
[TBL] [Abstract][Full Text] [Related]
12. A green tea polyphenol, epigalocatechin-3-gallate, induces apoptosis of human hepatocellular carcinoma, possibly through inhibition of Bcl-2 family proteins.
Nishikawa T; Nakajima T; Moriguchi M; Jo M; Sekoguchi S; Ishii M; Takashima H; Katagishi T; Kimura H; Minami M; Itoh Y; Kagawa K; Okanoue T
J Hepatol; 2006 Jun; 44(6):1074-82. PubMed ID: 16481065
[TBL] [Abstract][Full Text] [Related]
13. Anti-proliferative and anti-apoptotic potential effects of epigallocatechin-3-gallate and/or metformin on hepatocellular carcinoma cells: in vitro study.
Sabry D; Abdelaleem OO; El Amin Ali AM; Mohammed RA; Abdel-Hameed ND; Hassouna A; Khalifa WA
Mol Biol Rep; 2019 Apr; 46(2):2039-2047. PubMed ID: 30710234
[TBL] [Abstract][Full Text] [Related]
14. PGE
Zang S; Ma X; Wu Y; Liu W; Cheng H; Li J; Liu J; Huang A
Hum Pathol; 2017 May; 63():120-127. PubMed ID: 28300577
[TBL] [Abstract][Full Text] [Related]
15. The epigallocatechin gallate derivative Y6 reduces the cardiotoxicity and enhances the efficacy of daunorubicin against human hepatocellular carcinoma by inhibiting carbonyl reductase 1 expression.
Zhou H; Fu LX; Li L; Chen YY; Zhu HQ; Zhou JL; Lv MX; Gan RZ; Zhang XX; Liang G
J Ethnopharmacol; 2020 Oct; 261():113118. PubMed ID: 32621953
[TBL] [Abstract][Full Text] [Related]
16. Sensitization of TRAIL-induced apoptosis in human hepatocellular carcinoma HepG2 cells by phytochemicals.
Abou El Naga RN; Azab SS; El-Demerdash E; Shaarawy S; El-Merzabani M; Ammar el-SM
Life Sci; 2013 Mar; 92(10):555-61. PubMed ID: 23352978
[TBL] [Abstract][Full Text] [Related]
17. EP1 receptor is involved in prostaglandin E2-induced osteosarcoma growth.
Niu JC; Ma N; Liu W; Wang PJ
Bosn J Basic Med Sci; 2019 Aug; 19(3):265-273. PubMed ID: 30995899
[TBL] [Abstract][Full Text] [Related]
18. In vitro and in vivo study of epigallocatechin-3-gallate-induced apoptosis in aerobic glycolytic hepatocellular carcinoma cells involving inhibition of phosphofructokinase activity.
Li S; Wu L; Feng J; Li J; Liu T; Zhang R; Xu S; Cheng K; Zhou Y; Zhou S; Kong R; Chen K; Wang F; Xia Y; Lu J; Zhou Y; Dai W; Guo C
Sci Rep; 2016 Jun; 6():28479. PubMed ID: 27349173
[TBL] [Abstract][Full Text] [Related]
19. Epigallocatechin gallate induces chemopreventive effects on rats with diethylnitrosamine‑induced liver cancer via inhibition of cell division cycle 25A.
Tang Y; Cao J; Cai Z; An H; Li Y; Peng Y; Chen N; Luo A; Tao H; Li K
Mol Med Rep; 2020 Nov; 22(5):3873-3885. PubMed ID: 33000276
[TBL] [Abstract][Full Text] [Related]
20. [Epigallocatechin-3-gallate induces apoptosis in human hepatocellular carcinoma cells].
Chen XL; Wang Q; Cao LQ; Huang XH; Fu XH; Tan HX; Zhen MC; Chen JS
Zhonghua Yi Xue Za Zhi; 2008 Sep; 88(36):2524-8. PubMed ID: 19080641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
